Efficacy of Controlled-Release Paroxetine in the Treatment of Late-Life Depression
The DOI matches its Crossref record.
Abstract
BACKGROUND: Depression is the second most common neuropsychiatric disorder in older Americans, with significant clinical and public health costs. Despite advances in treatment, late-life depression remains a clinical challenge. Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition. METHOD: In this 12-week, multicenter, placebo-controlled, flexible-dose, double-blind, randomized trial, 319 elderly patients (mean age = 70 years) were treated with controlled-release paroxetine (paroxetine CR) up to 50 mg/day (N = 104), immediate-release paroxetine (paroxetine IR) up to 40 mg/day (N = 106), or placebo (N = 109). Patients met DSM-IV criteria for major depressive disorder and had a total score of 18 or more on the 17-item Hamilton Rating Scale for Depression (HAM-D). The primary efficacy measure was change from baseline to endpoint in HAM-D total score. RESULTS: The primary efficacy analysis showed an adjusted difference between change from baseline in HAM-D score for paroxetine CR and placebo of -2.6 (95% confidence interval [CI] = -4.47 to -0.73, p = .007) at the week 12 last-observation-carried-forward (LOCF) endpoint. The adjusted difference between paroxetine IR and placebo was -2.8 (95% CI = -4.65 to -0.99, p = .003) at week 12. Paroxetine CR and IR were more effective than placebo, with mean +/- SD endpoint HAM-D total scores of 10.0 +/- 7.41 and 10.0 +/- 7.10, respectively, for the active treatments compared with 12.6 +/- 7.34 for placebo. Response, defined as a score of 1 or 2 on the Clinical Global Impressions-global improvement scale, was achieved by 72% of paroxetine CR patients (LOCF; p < .002 vs. placebo), 65% of paroxetine IR patients (p = .06 vs. placebo), and 52% of placebo patients. Remission, defined as a HAM-D total score < or = 7, was achieved by 43% of paroxetine CR patients (LOCF; p = .009 vs. placebo), 44% of paroxetine IR patients (p = .01 vs. placebo), and 26% of placebo patients. In a post hoc analysis, mean HAM-D improvement for paroxetine CR and paroxetine IR was greater than for placebo in both chronically depressed patients (duration > 2 years) and those with short-term (< or = 2 years) depression. Dropout rates due to adverse events were 12.5% for paroxetine CR, 16.0% for paroxetine IR, and 8.3% for placebo. CONCLUSION: Paroxetine CR and paroxetine IR are effective and well tolerated treatments for major depressive disorder in elderly patients, including those with chronic depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Animal Models of Depression: Molecular Perspectives
Krishnan, V., & Nestler, E. J. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2010_108 · Cited by 528
“Even if major depression is accurately diagnosed and treated in all individuals with perfect treatment compliance, the best remission rates with standard antidepressants are only 30–40% (Rapaport et al. 2003; Trivedi et al. 2006).”
BackgroundTaylor, W. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1402180 · Cited by 394
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Nelson, J. C., Delucchi, K., & Schneider, L. S. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000308883.64832.ed · Cited by 230
Self-citationKok, R. M., Nolen, W. A., & Heeren, T. J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.02.036 · Cited by 167
Metadata
- Authors
- Rapaport, M. H., Schneider, L. S., Dunner, D. L., Davies, J. T., & Pitts, C. D.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-09-15
- Volume
- 64
- Issue
- 9
- Pages
- 1065-1074
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1994862345
- Cited by
- 109
- References
- 0
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Controlled-Release Paroxetine in the Treatment of Late-Life Depression. https://app.cochat.ai/papers/10.4088/jcp.v64n0912
- The paper
- Rapaport, M. H., Schneider, L. S., Dunner, D. L., Davies, J. T., & Pitts, C. D. (2003). Efficacy of Controlled-Release Paroxetine in the Treatment of Late-Life Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v64n0912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.